These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37166677)

  • 1. Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.
    Bruschi N; Malentacchi M; Malucchi S; Sperli F; Martire S; Sala A; Valentino P; Bertolotto A; Pautasso M; Capobianco MA
    Neurol Ther; 2023 Aug; 12(4):1375-1383. PubMed ID: 37166677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral CD19
    Ellrichmann G; Bolz J; Peschke M; Duscha A; Hellwig K; Lee DH; Linker RA; Gold R; Haghikia A
    J Neurol; 2019 Jan; 266(1):57-67. PubMed ID: 30377816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review.
    Abbadessa G; Miele G; Maida E; Minervini G; Lavorgna L; Bonavita S
    Mult Scler Relat Disord; 2022 Jul; 63():103926. PubMed ID: 35661568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders.
    Novi G; Bovis F; Capobianco M; Frau J; Mataluni G; Curti E; Zuliani L; Cavalla P; Brambilla L; Annovazzi P; Repice AM; Lanzillo R; Esposito S; Benedetti L; Maietta I; Sica F; Buttari F; Malucchi S; Fenu G; Landi D; Bosa C; Realmuto S; Malentacchi M; Granella F; Signori A; Bonavita S; Uccelli A; Sormani MP;
    Mult Scler Relat Disord; 2019 Nov; 36():101430. PubMed ID: 31610404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
    Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FCGR3A-V158F gene polymorphism: A potential predictor for rituximab dosing optimization in Chinese patients with neuromyelitis optica spectrum disorder.
    Cui L; Jiao J; Zhang Y; Wang R; Peng D; Jiao Y; Zhang W
    Mult Scler Relat Disord; 2024 Jun; 86():105600. PubMed ID: 38579568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders.
    Lebrun C; Cohen M; Rosenthal-Allieri MA; Bresch S; Benzaken S; Marignier R; Seitz-Polski B; Ticchioni M
    Neurol Ther; 2018 Dec; 7(2):373-383. PubMed ID: 29881979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailoring B cell depletion therapy in MS according to memory B cell monitoring.
    Novi G; Bovis F; Fabbri S; Tazza F; Gazzola P; Maietta I; Currò D; Bruschi N; Roccatagliata L; Boffa G; Lapucci C; Pesce G; Cellerino M; Solaro C; Laroni A; Capello E; Mancardi G; Sormani M; Inglese M; Uccelli A
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32753406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
    Ongphichetmetha T; Jitprapaikulsan J; Siritho S; Rattanathamsakul N; Detweeratham T; Prayoonwiwat N
    Sci Rep; 2024 Feb; 14(1):3503. PubMed ID: 38347079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    Spagni G; Sun B; Monte G; Sechi E; Iorio R; Evoli A; Damato V
    J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):62-69. PubMed ID: 36283808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica: Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab.
    Kim SH; Jeong IH; Hyun JW; Joung A; Jo HJ; Hwang SH; Yun S; Joo J; Kim HJ
    JAMA Neurol; 2015 Sep; 72(9):989-95. PubMed ID: 26167726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.
    Cohen M; Romero G; Bas J; Ticchioni M; Rosenthal M; Lacroix R; Brunet C; Rico A; Pelletier J; Audoin B; Lebrun C
    J Neurol Sci; 2017 Feb; 373():335-338. PubMed ID: 28131216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell proliferation characteristics and monitoring significance under the modified reduced-dose rituximab regimen for NMOSD: A real-world case series study.
    Cao S; Wang X; Ji X; Tian J; Zhu Y; Wang X; Gu Y; Duan X; Xiao X; Fang Q; Zhang X; Xue Q
    Mult Scler Relat Disord; 2023 Feb; 70():104524. PubMed ID: 36701910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting.
    Xiao H; Zeng W; Li L; Li L; Cui Y; Wang J; Ye J; Yang Q
    Front Neurol; 2020; 11():642. PubMed ID: 32733365
    [No Abstract]   [Full Text] [Related]  

  • 17. Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study.
    Zhao D; Ren K; Lu J; Liu Z; Li Z; Wu J; Xu Z; Wu S; Lei T; Ma C; Zhao S; Bai M; Li H; Guo J
    Front Immunol; 2023; 14():1148632. PubMed ID: 37614240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders.
    Correa-Díaz EP; Torres-Herrán GE; Miño Zambrano JE; Paredes-Gonzalez V; Caiza-Zambrano FJ
    Mult Scler Relat Disord; 2021 Feb; 48():102683. PubMed ID: 33338945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.
    Kim SH; Huh SY; Lee SJ; Joung A; Kim HJ
    JAMA Neurol; 2013 Sep; 70(9):1110-7. PubMed ID: 23897062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration.
    Tahara M; Oeda T; Okada K; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
    Mult Scler Relat Disord; 2022 Apr; 60():103730. PubMed ID: 35287025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.